Bio-Techne opens GMP manufacturing facility

By The Science Advisory Board staff writers

September 30, 2020 -- Bio-Techne has opened a 61,000-sq-ft good manufacturing practice (GMP) manufacturing facility in St. Paul, MN. The space will be dedicated to large-scale production of Escherichia coli-derived recombinant proteins for cell and gene-modified therapy workflows.

Chimeric antigen receptor (CAR) T-cell therapies and stem cell therapies have significantly increased the demand for GMP-grade recombinant proteins, which Bio-Techne plans to meet with the opening of the facility. The company invested $50 million to build and outfit the plant with advanced manufacturing and quality control technologies.

The facility houses multiple fermenters and purification suites and is expected to begin commercial production in early 2021, following validation procedures.

Bio-Techne rebrands genome engineering as part of R&D Systems portfolio
Bio-Techne has rebranded its cell and gene engineering product offer as part of its R&D Systems biotechnology brand.
Bio-Techne, Leica launch RNA probes for COVID-19 research
Bio-Techne and Leica Biosystems have announced the automation of RNAscope COVID-19 probes on Bond Rx, Leica's staining platform, for research use only....
Bio-Techne releases new SARS recombinant antibody
Bio-Techne has launched a SARS-CoV-1/2 spike receptor-binding domain LlamaBody recombinant antibody that blocks the virus from binding to the host receptor,...
Bio-Techne, Kantaro launch COVID-19 serology test
Bio-Techne and Kantaro Biosciences have launched COVID-SeroIndex, a quantitative SARS-CoV-2 immunoglobulin G antibody research-use only kit.
Bio-Techne releases product for manufacturing
Bio-Techne has released GMP ProDots Proteins to support cell and gene therapy manufacturing workflows. The product will allow manufacturers to safely...

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter